Patents Represented by Attorney Cozette M. McAvoy
  • Patent number: 8299081
    Abstract: A method for treating drug-resistant cancer, includes: administering to a patient in need thereof, a compound of formula I, a tautomer of the compound, a salt of the compound, a salt of the tautomer, a mixture thereof, or a pharmaceutical composition comprising the compound, the tautomer, the salt of the compound, the salt of the tautomer, or the mixture, wherein the patient is a cancer patient with drug-resistant cancer, wherein the compound of Formula I is as defined in the application.
    Type: Grant
    Filed: May 10, 2006
    Date of Patent: October 30, 2012
    Assignee: Novartis AG
    Inventors: Glenn C. Michelson, Vivien W. Chan, Carla C. Heise, Marion Wiesmann, Timothy D. Dawes
  • Patent number: 8222413
    Abstract: A method for synthesizing a heterocyclic compound includes: reacting 1-methylpiperazine with 5-chloro-2-nitroaniline at an internal temperature sufficient to provide a compound of Formula VIH The 1-methylpiperazine and the 5-chloro-2-nitroaniline are reacted in a solvent that comprises water in an amount greater than 50 percent by volume based on the amount of the solvent and/or are reacted in a solvent that comprises an organic solvent component that has a boiling point of greater than 100° C. at atmospheric pressure.
    Type: Grant
    Filed: May 17, 2006
    Date of Patent: July 17, 2012
    Assignee: Novartis AG
    Inventors: Gabriel Galvin, Eric Harwood, David Ryckman, Shuguang Zhu
  • Patent number: 8198450
    Abstract: Compounds of formula I in salt or solvate form, wherein W, Rx, Ry, R1, R2, R3, R4, R5, R6 and R7 and A have the meanings as indicated in the specification, are useful for treating diseases mediated by the ?2-adrenoreceptor. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.
    Type: Grant
    Filed: July 2, 2007
    Date of Patent: June 12, 2012
    Assignee: Novartis AG
    Inventors: Olivier Lohse, Stephanie Monnier, Jean-Louis Reber
  • Patent number: 8168654
    Abstract: Compounds of formula I in salt or zwitterionic form wherein, wherein R1, R2, R3, and R4 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by the muscarinic M3 receptor. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.
    Type: Grant
    Filed: October 20, 2009
    Date of Patent: May 1, 2012
    Assignee: Novartis AG
    Inventors: Stephen P Collingwood, Brian Cox, Urs Baettig, Gurdip Bhalay, Nicholas J Devereux
  • Patent number: 8158360
    Abstract: Methods of utilizing biomarkers to identify patients for treatment or to monitor response to treatment are taught herein. Alterations in levels of gene expression of the biomarkers, particularly in response to FGFR3 inhibition, are measured and identifications or adjustments may be made accordingly.
    Type: Grant
    Filed: December 7, 2006
    Date of Patent: April 17, 2012
    Assignee: Novartis AG
    Inventors: Carla Heise, Esther Masih-Khan, Edward Moler, Michael Rowe, Keith Stewart, Suzanne Trudel
  • Patent number: 8153669
    Abstract: Compounds of formula (I), in salt or zwitterionic form, wherein J, L, M, R1, R2, R3, R4 and R5 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by the muscarinic M3 receptor. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.
    Type: Grant
    Filed: December 22, 2005
    Date of Patent: April 10, 2012
    Assignee: Novartis AG
    Inventors: Neil John Press, Stephen Paul Collingwood
  • Patent number: 8119105
    Abstract: The invention relates to an aerosol container for pharmaceutically active aerosols that are to be administered in predetermined amounts and that are supplied in the container in the form of a suspension, the suspension also comprising, in addition to a pharmaceutically active substance, at least a propellant gas. The aerosol container has a metering valve that comprises a metering chamber and a valve stem. In a first position of the valve stem, the metering chamber is in communication with the interior of the container and has been filled with a predetermined amount of the aerosol. In a second position of the valve stem, the amount of aerosol disposed in the metering chamber is released. The propellant gas is an alternative propellant gas that is free of fluorochlorohydrocarbons, preferably a propellant gas that comprises only fluorohydrocarbons, and the inner wall of the container is coated with a plastics coating.
    Type: Grant
    Filed: April 28, 2003
    Date of Patent: February 21, 2012
    Assignee: Novartis Corporation
    Inventors: Francois Brugger, Angelika Stampf
  • Patent number: 8084463
    Abstract: Compounds of Formula (I); in salt or zwitterionic form wherein R1, R2, R3 and R4 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by the muscarinic M3 receptor, especially inflammatory or obstructive airways diseases. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.
    Type: Grant
    Filed: March 11, 2010
    Date of Patent: December 27, 2011
    Assignee: Novartis AG
    Inventors: Neil J Press, Stephen P Collingwood, Urs Baettig, Brian Cox, Sudhakar D Garad, Hyungchul Kim, Dimitris Papoutsakis, Simon J Watson
  • Patent number: 8067437
    Abstract: Compounds of formula in free or salt or solvate form, where Ar is a group of formula Y is carbon or nitrogen and R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, X, n, p, q and r are as defined in the specification, their preparation and their use as pharmaceuticals, particularly for the treatment of obstructive or inflammatory airways diseases.
    Type: Grant
    Filed: September 20, 2010
    Date of Patent: November 29, 2011
    Assignee: Novartis AG
    Inventors: Bernard Cuenoud, Ian Bruce, Robin A Fairhurst, David Beattie
  • Patent number: 7947730
    Abstract: Compounds of formula I in salt or zwitterionic form wherein, wherein R1, R2, R3, R4, R5, J, L and M have the meanings as indicated in the specification, are useful for treating conditions that are mediated by the muscarinic M3 receptor. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.
    Type: Grant
    Filed: June 23, 2004
    Date of Patent: May 24, 2011
    Assignee: Novartis AG
    Inventors: Stephen Paul Collingwood, Urs Baettig, Clive McCarthy
  • Patent number: 7825095
    Abstract: A patient suffering from an endobronchial infection is treated by administering to the patient for inhalation a dose of less than about 4.0 ml of a nebulized aerosol formulation comprising from about 60 to about 200 mg/ml of an aminoglycoside antibiotic, such as tobramycin, in a physiologically acceptable carrier in a time period of less than about 10 minutes. Unit dose devices for storage and delivery of the aminoglycoside antibiotic formulations are also provided.
    Type: Grant
    Filed: October 24, 2007
    Date of Patent: November 2, 2010
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Robert John Speirs, Barbara Ann Schaeffler, Peter Bruce Challoner
  • Patent number: 7820694
    Abstract: Compounds of formula in free or salt or solvate form, where Ar is a group of formula Y is carbon or nitrogen and R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, X, n, p, q and r are as defined in the specification, their preparation and their use as pharmaceuticals, particularly for the treatment of obstructive or inflammatory airways diseases.
    Type: Grant
    Filed: October 13, 2009
    Date of Patent: October 26, 2010
    Assignee: Novartis AG
    Inventors: Bernard Cuenoud, Ian Bruce, Robin A Fairhurst, David Beattie
  • Patent number: 7745462
    Abstract: Compounds of formula I in free or salt form, wherein —C—Y—, R1 and R2 are G have the meanings as indicated in the specification, are useful for treating conditions that are prevented or alleviated by activation of the ?2-adrenoreceptor. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.
    Type: Grant
    Filed: April 2, 2004
    Date of Patent: June 29, 2010
    Assignee: Novartis AG
    Inventors: Robin Alec Fairhurst, David Andrew Sandham, David Beattie, Ian Bruce, Bernard Cuenoud, Reamonn Madden, Neil John Press, Roger John Taylor, Katharine Louise Turner, Simon James Watson
  • Patent number: 7740842
    Abstract: The present invention provides stable liquid formulations of antibodies suitable for parenteral administration. Also, provided are aqueous solutions which have high concentrations of therapeutical antibodies which may be used to produce therapeutical liquid formulations. The present invention also relates to uses, such as medical uses, of the stable liquid formulations and processes for the production of the stable liquid formulations.
    Type: Grant
    Filed: January 24, 2006
    Date of Patent: June 22, 2010
    Assignee: Novartis AG
    Inventors: Tudor Arvinte, Pierre F Fauquex
  • Patent number: 7723356
    Abstract: Compounds of Formula (I); in salt or zwitterionic form wherein R1, R2, R3 and R4 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by the muscarinic M3 receptor, especially inflammatory or obstructive airways diseases. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.
    Type: Grant
    Filed: October 31, 2005
    Date of Patent: May 25, 2010
    Assignee: Novartis AG
    Inventors: Neil John Press, Stephen Paul Collingwood, Urs Baettig, Brian Cox, Sudhakar Devidasrao Garad, Hyungchul Kim, Dimitris Papoutsakis, Simon James Watson
  • Patent number: 7683048
    Abstract: Polymorphic crystal forms of 3-methylthiophene-2-carboxylic acid (6S,9R,10S,11S,13S,16R, 17R)-9-chloro-6-fluoro-11-hydroxy-17-methoxycarbonyl-10,13,16-trimethyl-3-oxo-6,7,8,9,10, 11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl ester. The crystal forms possess anti-inflammatory activity and have very good stability. Methods for preparing the crystal forms are also described.
    Type: Grant
    Filed: July 28, 2003
    Date of Patent: March 23, 2010
    Assignee: Novartis AG
    Inventors: Guido Jordine, Michael Mutz
  • Patent number: 7662369
    Abstract: Stabilized pharmaceutical formulations comprising IFN-? and highly purified mannitol are provided. The highly purified mannitol stabilizes the compositions by reducing the formation of IFN-? adducts in comparison with IFN-? formulated with mannitol that has not been highly purified. Methods for increasing the stability of IFN-? or a variant thereof in a liquid or lyophilized composition and for increasing storage stability of such a composition are also provided.
    Type: Grant
    Filed: July 22, 2005
    Date of Patent: February 16, 2010
    Assignee: Novartis AG
    Inventors: Sidney N. Wolfe, Maninder S. Hora
  • Patent number: 7622484
    Abstract: A medicament comprising, separately or together, (A) a compound of formula (I) in free or pharmaceutically acceptable salt or solvate form and (B) a corticosteroid, for simultaneous, sequential or separate administration in the treatment of an inflammatory or obstructive airways disease, the molar ratio of (A) to (B) being from 100:1 to 1:300.
    Type: Grant
    Filed: October 12, 2005
    Date of Patent: November 24, 2009
    Assignee: Novartis AG
    Inventors: Bernard Cuenoud, Robin A Fairhurst, Nicholas Lowther
  • Patent number: 7622483
    Abstract: Compounds of formula in free or salt or solvate form, where Ar is a group of formula Y is carbon or nitrogen and R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, X, n, p, q and r are as defined in the specification, their preparation and their use as pharmaceuticals, particularly for the treatment of obstructive or inflammatory airways diseases.
    Type: Grant
    Filed: March 7, 2005
    Date of Patent: November 24, 2009
    Assignee: Novartis AG
    Inventors: Bernard Cuenoud, Ian Bruce, Robin A Fairhurst, David Beattie
  • Patent number: 7605267
    Abstract: The invention relates to a process for preparing 5-(?-haloacetyl)-8-substituted oxy-(1H)-quinolin-2-ones.
    Type: Grant
    Filed: April 1, 2004
    Date of Patent: October 20, 2009
    Assignee: Novartis AG
    Inventors: Olivier Lohse, Gerhard Penn, Hanspeter Schilling